Hypercholesterolemia
Conditions
Brief summary
A prospective, open, observational study to confirm the lipid-lowering effect, changes in glucose metabolism, and safety after 6 months of administration of atostazet to hypercholesterolemic patients 65 years of age or older
Interventions
None listed
Sponsors
Dong Wha Pharmaceutical Co. Ltd.
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Males or females aged ≥ 65 years * Primary Hypercholesterolemia * moderate risk or higher patient based on Korean Guidelines for the Management of Dyslipidemia (the 4th edition)
Exclusion criteria
* Patients with a known hypersensitivity to any of the major or minor components of the study drug * Patients with active hepatic disease or unexplained persistently elevated serum aminotransferase levels * Patients with myopathies * Patients receiving glecaprevir and pibrentasvir
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of Adverse events | 24 weeks to the base | Incidence of Adverse events |
Countries
South Korea
Outcome results
None listed